Table 2.
Treatment-related AEs
| Patients, n (%) N = 11 |
|||
|---|---|---|---|
| Related to V937 | Related to ipilimumab | Overall | |
| Patients with any treatment-related AE | 9 (82) | 10 (91) | 10 (91) |
| Treatment-related AEs occurring in > 1 patienta | |||
| Chills | 3 (27) | 1 (9) | 3 (27) |
| Fatigue | 3 (27) | 4 (36) | 5 (45) |
| Myalgia | 3 (27) | 3 (27) | 4 (36) |
| Leukopenia | 2 (18) | 0 | 2 (18) |
| Nausea | 2 (18) | 2 (18) | 3 (27) |
| Pruritus | 2 (18) | 3 (27) | 3 (27) |
| Arthralgia | 1 (9) | 3 (27) | 3 (27) |
| Diarrhea | 1 (9) | 5 (45) | 6 (55) |
| Headache | 1 (9) | 1 (9) | 2 (18) |
| Maculopapular rash | 1 (9) | 1 (9) | 2 (18) |
AE adverse event
aAll treatment-related AEs were grade 1 or 2 with the exception of ipilimumab-related grade 3 diarrhea in 2 patients. No grade 4 or 5 treatment-related AEs were reported